Look­ing for first-in-class glo­ry, Boehringer In­gel­heim ac­quires two pre­clin­i­cal can­cer drugs from Ver­sant-backed biotech

Wad­ing deep­er in­to the next wave of im­muno-on­col­o­gy, Boehringer In­gel­heim has bought up a Ver­sant-launched pre­clin­i­cal pipeline fo­cused on the tu­mor mi­croen­vi­ron­ment.

The ac­qui­si­tion of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.